Coronary collateral growth-Back to the future

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 4, 2012, Pages 905-911

  Chilian, William M ^a   Penn, Marc S ^a,b   Pung, Yuh Fen ^a   Dong, Feng ^a,b   Mayorga, Maritza ^a,b   Ohanyan, Vahagn ^a   Logan, Suzanna ^a   Yin, Liya ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Skirball Center for Stem Cell Research   (United States)

Author keywords

Angiogenesis; Arteriogenesis; Collateral circulation; Coronary circulation; Coronary collaterals

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOSTATIN; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; VASCULOTROPIN;

ANGIOGENESIS; BFGF GENE; CARDIOVASCULAR RISK; CELL INFILTRATION; CELL VIABILITY; CORONARY ARTERY COLLATERAL CIRCULATION; ENDOTHELIAL DYSFUNCTION; EXERCISE; GENE; GENE THERAPY; GROWTH INHIBITION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MONONUCLEAR CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL; VEGF GENE;

COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84858291159     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.12.006     Document Type: Review

References (127)

1. Schaper W., De Brabander M., Lewi P. DNA synthesis and mitoses in coronary collateral vessels of the dog. Circ Res 1971, 28:671-679.
2. Schaper W. Therapeutic arteriogenesis has arrived. Circulation 2001, 104:1994-1995.
3. Schaper W., Gorge G., Winkler B., Schaper J. The collateral circulation of the heart. Prog Cardiovasc Dis 1988, 31:57-77.
4. Schaper W., Ito W.D. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996, 79:911-919.
5. Schaper W., Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003, 23:1143-1151.
6. Schaper W. Coronary collaterals. Int Soc Appl Cardiovasc Biol 1991, 2:25-30.
7. Schaper W. Collateral circulation: past and present. Basic Res Cardiol 2009, 104:5-21.
8. Simons M. Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed?. J Am Coll Cardiol 2005, 46:835-837.
9. de Muinck E.D., Simons M. Re-evaluating therapeutic neovascularization. J Mol Cell Cardiol 2004, 36:25-32.
10. Baklanov D., Simons M. Arteriogenesis: lessons learned from clinical trials. Endothelium 2003, 10:217-223.
11. Post M.J., Simons M. The rational phase of therapeutic angiogenesis. Minerva Cardioangiol 2003, 51:421-432.
12. Laham R.J., Simons M., Sellke F. Gene transfer for angiogenesis in coronary artery disease. Annu Rev Med 2001, 52:485-502.
13. Pung Y.F., Chilian W.M. Corruption of coronary collateral growth in metabolic syndrome: role of oxidative stress. World J Cardiol 2010, 2:421-427.
14. Yun J., Rocic P., Pung Y.F., Belmadani S., Carrao A.C., Ohanyan V., et al. Redox-dependent mechanisms in coronary collateral growth: the "redox window" hypothesis. Antioxid Redox Signal 2009, 11:1961-1974.
15. Schaper W. The collateral circulation of the heart 1971, Elsevier, New York, N.Y.
16. Schaper W., Schaper J. Arteriogenesis 2004, Kluwer Academic Publishers, Boston.
17. Schaper W., Schaper J. Collateral circulation: heart, brain, kidney, limbs 1993, Kluwer Academic Publishers, Boston.
18. Hochberg I., Roguin A., Nikolsky E., Chanderashekhar P.V., Cohen S., Levy A.P. Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 2002, 161:441-446.
19. Roguin A., Resar J.R. Genetics and susceptibility of coronary collateral formation. Circulation 2003, 108:e149. [author reply e].
20. Lamblin N., Cuilleret F.J., Helbecque N., Dallongeville J., Lablanche J.M., Amouyel P., et al. A common variant of endothelial nitric oxide synthase (Glu298Asp) is associated with collateral development in patients with chronic coronary occlusions. BMC Cardiovasc Disord 2005, 5:27.
21. Gulec S., Karabulut H., Ozdemir A.O., Ozdol C., Turhan S., Altin T., et al. Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development. Atherosclerosis 2008, 198:354-359.
22. Zhang J., Regieli J.J., Schipper M., Entius M.M., Liang F., Koerselman J., et al. Inflammatory gene haplotype-interaction networks involved in coronary collateral formation. Hum Hered 2008, 66:252-264.
23. Meier P., Antonov J., Zbinden R., Kuhn A., Zbinden S., Gloekler S., et al. Non-invasive gene-expression-based detection of well-developed collateral function in individuals with and without coronary artery disease. Heart 2009, 95:900-908.
24. Schaper W. Tangential wall stress as a molding force in the development of collateral vessels in the canine heart. Experientia 1967, 23:595-596.
25. Schaper W., Jageneau A., Xhonneux R. The development of collateral circulation in the pig and dog heart. Cardiologia 1967, 51:321-335.
26. Schaper W. Influence of physical factors on the radial growth of collateral vessels in coronary circulation. Verh Dtsch Ges Kreislaufforsch 1966, 32:282-286.
27. Schaper W.K., Xhonneux R., Jageneau A.H. Stimulation of the coronary collateral circulation by lidoflazine (R 7904). Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1965, 252:1-8.
28. Chilian W.M., Mass H.J., Williams S.E., Layne S.M., Smith E.E., Scheel K.W. Microvascular occlusions promote coronary collateral growth. Am J Physiol 1990, 258:H1103-H1111.
29. van den Wijngaard J.P., Schulten H., van Horssen P., Ter Wee R.D., Siebes M., Post M.J., et al. Porcine coronary collateral formation in the absence of a pressure gradient remote of the ischemic border zone. Am J Physiol Heart Circ Physiol 2011, 300:H1930-H1937.
30. Weihrauch D., Tessmer J., Warltier D.C., Chilian W.M. Repetitive coronary artery occlusions induce release of growth factors into the myocardial interstitium. Am J Physiol 1998, 275:H969-H976.
31. Rocic P., Kolz C., Reed R., Potter B., Chilian W.M. Optimal reactive oxygen species concentration and p38 MAP kinase are required for coronary collateral growth. Am J Physiol Heart Circ Physiol 2007, 292:H2729-H2736.
32. Kuo L., Davis M.J., Cannon S., Chilian W.M. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by l-argine. Circ Res 1992, 70:465-476.
33. Simons M., Bonow R.O., Chronos N.A., Cohen D.J., Giordano F.J., Hammond H.K., et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000, 102:E73-E86.
34. Emanueli C., Madeddu P. Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions. Br J Pharmacol 2001, 133:951-958.
35. Losordo D.W., Vale P.R., Isner J.M. Gene therapy for myocardial angiogenesis. Am Heart J 1999, 138:S132-S141.
36. Hattan N., Warltier D., Gu W., Kolz C., Chilian W.M., Weihrauch D. Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth. Am J Physiol Heart Circ Physiol 2004, 287:H488-H493.
37. Bauters C., Asahara T., Zheng L.P., Takeshita S., Bunting S., Ferrara N., et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995, 21:314-324. [discussion 24-5].
38. Takeshita S., Pu L.Q., Stein L.A., Sniderman A.D., Bunting S., Ferrara N., et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994, 90:II228-II234.
39. Takeshita S., Weir L., Chen D., Zheng L.P., Riessen R., Bauters C., et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 1996, 227:628-635.
40. Takeshita S., Zheng L.P., Brogi E., Kearney M., Pu L.Q., Bunting S., et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994, 93:662-670.
41. Tsurumi Y., Takeshita S., Chen D., Kearney M., Rossow S.T., Passeri J., et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996, 94:3281-3290.
42. van der Zee R., Murohara T., Luo Z., Zollmann F., Passeri J., Lekutat C., et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997, 95:1030-1037.
43. Srivastava S., Terjung R.L., Yang H.T. Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003, 285:H1190-H1197.
44. Yang H.T., Yan Z., Abraham J.A., Terjung R.L. VEGF(121)- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Am J Physiol Heart Circ Physiol 2001, 280:H1097-H1104.
45. Lopez J.J., Edelman E.R., Stamler A., Hibberd M.G., Prasad P., Thomas K.A., et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol 1998, 274:H930-H936.
46. Lopez J.J., Edelman E.R., Stamler A., Morgan J.P., Sellke F.W., Simons M. Local perivascular administration of basic fibroblast growth factor: drug delivery and toxicological evaluation. Drug Metab Dispos 1996, 24:922-924.
47. Sellke F.W., Li J., Stamler A., Lopez J.J., Thomas K.A., Simons M. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 1996, 120:182-188.
48. Banai S., Jaklitsch M.T., Shou M., Lazarous D.F., Scheinowitz M., Biro S., et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994, 89:2183-2189.
49. Unger E.F., Banai S., Shou M., Lazarous D.F., Jaklitsch M.T., Scheinowitz M., et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994, 266:H1588-H1595.
50. Tirziu D., Moodie K.L., Zhuang Z.W., Singer K., Helisch A., Dunn J.F., et al. Delayed arteriogenesis in hypercholesterolemic mice. Circulation 2005, 112:2501-2509.
51. Matsunaga T., Moniz M., Tessmmer J., Weirauch D., Chilian W.M. Role of nitric oxide and vascular endothelial growth factor in coronary collateral growth. Circulation 2000, 102:3098-3103.
52. Reed R., Kolz C., Potter B., Rocic P. The mechanistic basis for the disparate effects of angiotensin II on coronary collateral growth. Arterioscler Thromb Vasc Biol 2008, 28:61-67.
53. Hattan N., Chilian W.M., Park F., Rocic P. Restoration of coronary collateral growth in the Zucker obese rat: impact of VEGF and ecSOD. Basic Res Cardiol 2007, 102:217-223.
54. Lassaletta A.D., Chu L.M., Sellke F.W. Therapeutic neovascularization for coronary disease: current state and future prospects. Basic Res Cardiol 2011, 106:897-909.
55. Lincoln T.M., Dey N.B., Boerth N.J., Cornwell T.L., Soff G.A. Nitric oxide-cyclic GMP pathway regulates vascular smooth muscle cell phenotypic modulation: implications in vascular diseases. Acta Physiol Scand 1998, 164:507-515.
56. Boerth N.J., Dey N.B., Cornwell T.L., Lincoln T.M. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. J Vasc Res 1997, 34:245-259.
57. Lincoln T.M., Dey N., Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 2001, 91:1421-1430.
58. Seraia I.P., Nartsissov Ia R., Brown G. Mathematical modeling of non-stationary spatial gradients of nitric oxide in the muscle wall of blood vessels. Biofizika 2003, 48:91-96.
59. Orlic D., Kajstura J., Chimenti S., Limana F., Jakoniuk I., Quaini F., et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001, 98:10344-10349.
60. Leri A., Hosoda T., Kajstura J., Anversa P., Rota M. Identification of a coronary stem cell in the human heart. J Mol Med (Berl) 2011, 89:947-959.
61. Leri A., Kajstura J., Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005, 85:1373-1416.
62. Nadal-Ginard B., Anversa P., Kajstura J., Leri A. Cardiac stem cells and myocardial regeneration. Novartis Foundation symposium 2005, 265:142-154. (discussion 55-7, 204-11).
63. Orlic D., Kajstura J., Chimenti S., Bodine D.M., Leri A., Anversa P. Bone marrow stem cells regenerate infarcted myocardium. Pediatr Transplant 2003, 7(Suppl. 3):86-88.
64. Penn M.S., Zhang M., Deglurkar I., Topol E.J. Role of stem cell homing in myocardial regeneration. Int J Cardiol 2004, 95(Suppl. 1):S23-S25.
65. Chavakis E., Carmona G., Urbich C., Gottig S., Henschler R., Penninger J.M., et al. Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. Circ Res 2008, 102:942-949.
66. Agarwal U., Ghalayini W., Dong F., Weber K., Zou Y.R., Rabbany S.Y., et al. Role of cardiac myocyte CXCR4 expression in development and left ventricular remodeling after acute myocardial infarction. Circ Res 2010, 107:667-676.
67. Askari A.T., Penn M.S. Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration. Discov Med 2003, 3:46-47.
68. Schenk S., Mal N., Finan A., Zhang M., Kiedrowski M., Popovic Z., et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007, 25:245-251.
69. Zhang M., Mal N., Kiedrowski M., Chacko M., Askari A.T., Popovic Z.B., et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007, 21:3197-3207.
70. Dimmeler S., Vasa-Nicotera M. Aging of progenitor cells: limitation for regenerative capacity?. J Am Coll Cardiol 2003, 42:2081-2082.
71. Urbich C., Heeschen C., Aicher A., Dernbach E., Zeiher A.M., Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003, 108:2511-2516.
72. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346.
73. Walter D.H., Dimmeler S. Endothelial progenitor cells: regulation and contribution to adult neovascularization. Herz 2002, 27:579-588.
74. Rehman J., Traktuev D., Li J., Merfeld-Clauss S., Temm-Grove C.J., Bovenkerk J.E., et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109:1292-1298.
75. Traktuev D.O., Merfeld-Clauss S., Li J., Kolonin M., Arap W., Pasqualini R., et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 2008, 102:77-85.
76. Schachinger V., Assmus B., Britten M.B., Honold J., Lehmann R., Teupe C., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J Am Coll Cardiol 2004, 44:1690-1699.
77. Schachinger V., Assmus B., Honold J., Lehmann R., Hofmann W.K., Martin H., et al. Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. Clin Res Cardiol 2006, 95:13-22.
78. Heusch G. SCIPIO brings new momentum to cardiac cell therapy. Lancet 2011, 378:1827-1828.
79. Lunde K., Solheim S., Aakhus S., Arnesen H., Abdelnoor M., Egeland T., et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006, 355:1199-1209.
80. Schachinger V., Erbs S., Elsasser A., Haberbosch W., Hambrecht R., Holschermann H., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
81. Abdel-Latif A., Bolli R., Tleyjeh I.M., Montori V.M., Perin E.C., Hornung C.A., et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007, 167:989-997.
82. Assmus B., Schachinger V., Teupe C., Britten M., Lehmann R., Dobert N., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017.
83. Marban E., Cheng K. Heart to heart: the elusive mechanism of cell therapy. Circulation 2010, 121:1981-1984.
84. Yoon C.H., Koyanagi M., Iekushi K., Seeger F., Urbich C., Zeiher A.M., et al. Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation 2010, 121:2001-2011.
85. Ziebart T., Yoon C.H., Trepels T., Wietelmann A., Braun T., Kiessling F., et al. Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res 2008, 103:1327-1334.
86. Zaruba M.M., Soonpaa M., Reuter S., Field L.J. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation 2010, 121:1992-2000.
87. Sundararaman S., Miller T.J., Pastore J.M., Kiedrowski M., Aras R., Penn M.S. Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure. Gene Ther 2011, 18:867-873.
88. Askari A.T., Unzek S., Popovic Z.B., Goldman C.K., Forudi F., Kiedrowski M., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
89. Deglurkar I., Mal N., Mills W.R., Popovic Z.B., McCarthy P., Blackstone E.H., et al. Mechanical and electrical effects of cell-based gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther 2006, 17:1144-1151.
90. Ripa R.S., Jorgensen E., Baldazzi F., Frikke-Schmidt R., Wang Y., Tybjaerg-Hansen A., et al. The influence of genotype on vascular endothelial growth factor and regulation of myocardial collateral blood flow in patients with acute and chronic coronary heart disease. Scand J Clin Lab Invest 2009, 69:722-728.
91. Lin T.H., Wang C.L., Su H.M., Hsu P.C., Juo S.H., Voon W.C., et al. Functional vascular endothelial growth factor gene polymorphisms and diabetes: effect on coronary collaterals in patients with significant coronary artery disease. Clin Chim Acta 2010, 411:1688-1693.
92. Resar J.R., Roguin A., Voner J., Nasir K., Hennebry T.A., Miller J.M., et al. Hypoxia-inducible factor 1alpha polymorphism and coronary collaterals in patients with ischemic heart disease. Chest 2005, 128:787-791.
93. Ceyhan K., Kadi H., Celik A., Burucu T., Koc F., Sogut E., et al. Angiotensin-converting enzyme DD polymorphism is associated with poor coronary collateral circulation in patients with coronary artery disease. J Investig Med 2012, 60(1):49-55.
94. van der Laan A.M., Schirmer S.H., de Vries M.R., Koning J.J., Volger O.L., Fledderus J.O., et al. Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. Eur Heart J 2011, Aug 10 [Electronic publication ahead of print].
95. Bagavandoss P., Wilks J.W. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem Biophys Res Commun 1990, 170:867-872.
96. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990, 87:6624-6628.
97. Iruela-Arispe M.L., Bornstein P., Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A 1991, 88:5026-5030.
98. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584.
99. Stenina O.I., Byzova T.V., Adams J.C., McCarthy J.J., Topol E.J., Plow E.F. Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol 2004, 36:1013-1030.
100. Topol E.J., McCarthy J., Gabriel S., Moliterno D.J., Rogers W.J., Newby L.K., et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001, 104:2641-2644.
101. Boekholdt S.M., Trip M.D., Peters R.J., Engelen M., Boer J.M., Feskens E.J., et al. Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol 2002, 22:e24-e27.
102. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
103. Kuo C.J., Farnebo F., Yu E.Y., Christofferson R., Swearingen R.A., Carter R., et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 2001, 98:4605-4610.
104. Hahnfeldt P., Panigrahy D., Folkman J., Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999, 59:4770-4775.
105. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
106. Folkman J. Endogenous inhibitors of angiogenesis. Harvey Lect 1996, 92:65-82.
107. Matsunaga T., Weihrauch D.W., Moniz M.C., Tessmer J., Warltier D.C., Chilian W.M. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 2002, 105:2185-2191.
108. Matsunaga T., Chilian W.M., March K. Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease. Am J Physiol Heart Circ Physiol 2005, 288:H2042-H2046.
109. Mitsuma W., Kodama M., Hanawa H., Ito M., Ramadan M.M., Hirono S., et al. Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. Am J Cardiol 2007, 99:494-498.
110. Fujita M., Nakae I., Kihara Y., Hasegawa K., Nohara R., Ueda K., et al. Determinants of collateral development in patients with acute myocardial infarction. Clin Cardiol 1999, 22:595-599.
111. Fujita M., McKown D.P., McKown M.D., Franklin D. Effects of glyceryl trinitrate on functionally regressed newly developed collateral vessels in conscious dogs. Cardiovasc Res 1988, 22:639-647.
112. Teng C.J., Lachapelle K., Chiu R.C. Reappraisal of recent clinical trials of angiogenic therapy in myocardial ischemia. Asian Cardiovasc Thorac Ann 2005, 13:90-97.
113. 2 for vascular smooth muscle cells is mediated by an increase of the affinity of basic fibroblast growth factor for its receptor. FEBS Lett 1996, 395:43-47.
114. Denenberg D.L. The effects of exercise on the coronary collateral circulation. J Sports Med Phys Fitness 1972, 12:76-81.
115. Cohen M.V., Yipintsoi T., Malhotra A., Penpargkul S., Scheuer J. Effect of exercise on collateral development in dogs with normal coronary arteries. J Appl Physiol 1978, 45:797-805.
116. Neill W.A., Oxendine J.M. Exercise can promote coronary collateral development without improving perfusion of ischemic myocardium. Circulation 1979, 60:1513-1519.
117. Scheel K.W., Ingram L.A., Wilson J.L. Effects of exercise on the coronary and collateral vasculature of beagles with and without coronary occlusion. Circ Res 1981, 48:523-530.
118. Roth D.M., White F.C., Nichols M.L., Dobbs S.L., Longhurst J.C., Bloor C.M. Effect of long-term exercise on regional myocardial function and coronary collateral development after gradual coronary artery occlusion in pigs. Circulation 1990, 82:1778-1789.
119. Vogel R., Traupe T., Steiger V.S., Seiler C. Physical coronary arteriogenesis: a human "model" of collateral growth promotion. Trends Cardiovasc Med 2010, 20:129-133.
120. Pagonas N., Utz W., Schulz-Menger J., Busjahn A., Monti J., Thierfelder L., et al. Assessment of the effect of external counterpulsation on myocardial adaptive arteriogenesis by invasive functional measurements-design of the arteriogenesis network trial 2. Int J Cardiol 2010, 145:432-437.
121. Fujita M., Sasayama S. Coronary collateral growth and its therapeutic application to coronary artery disease. Circ J 2010, 74:1283-1289.
122. Yin L., Ohanyan V., Fen Pung Y., Delucia A., Bailey E., Enrick M., et al. Induction of vascular progenitor cells from endothelial cells stimulates coronary collateral growth. Circ Res 2012, 110(1).
123. Belmadani S., Matrougui K., Kolz C., Pung Y.F., Palen D., Prockop D.J., et al. Amplification of coronary arteriogenic capacity of multipotent stromal cells by epidermal growth factor. Arterioscler Thromb Vasc Biol 2009, 29:802-808.
124. Carrao A.C., Chilian W.M., Yun J., Kolz C., Rocic P., Lehmann K., et al. Stimulation of coronary collateral growth by granulocyte stimulating factor: role of reactive oxygen species. Arterioscler Thromb Vasc Biol 2009, 29:1817-1822.
125. Penn M.S. SDF-1:CXCR4 axis is fundamental for tissue preservation and repair. Am J Pathol 2010, 177:2166-2168.
126. Penn M.S. Importance of the SDF-1:CXCR4 axis in myocardial repair. Circ Res 2009, 104:1133-1135.
127. Ren B., Deng Y., Mukhopadhyay A., Lanahan A.A., Zhuang Z.W., Moodie K.L., et al. ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J Clin Invest 2010, 120:1217-1228.